This is a contrast between Intec Pharma Ltd. (NASDAQ:NTEC) and Cellectis S.A. (NASDAQ:CLLS) based on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intec Pharma Ltd.||N/A||0.00||41.18M||-1.40||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 shows Intec Pharma Ltd. and Cellectis S.A.â€™s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Intec Pharma Ltd.||0.00%||0%||0%|
The table given features the ratings and recommendations for Intec Pharma Ltd. and Cellectis S.A.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Intec Pharma Ltd.||0||0||0||0.00|
Competitively Cellectis S.A. has a consensus price target of $25, with potential upside of 47.67%.
Institutional & Insider Ownership
Roughly 40.62% of Intec Pharma Ltd. shares are held by institutional investors while 29.4% of Cellectis S.A. are owned by institutional investors. About 11.4% of Intec Pharma Ltd.â€™s share are held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intec Pharma Ltd.||10.98%||30.61%||110.41%||72.58%||44.91%||49.13%|
For the past year Intec Pharma Ltd. has 49.13% stronger performance while Cellectis S.A. has -33.55% weaker performance.
On 6 of the 10 factors Intec Pharma Ltd. beats Cellectis S.A.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÃ‚â€™s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÃ‚â€™s disease symptoms in advanced ParkinsonÃ‚â€™s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÃ‚â€™s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.